SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.

Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO)

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed comp

Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Ou

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2

Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% i

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the an

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) have earned an average recomm

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering alloge

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potent

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients wit

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in fir

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers f

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progr

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the an

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a

Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises

US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir

Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect A

Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market P

Argus Research analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Mar

Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Out

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and rai

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a

Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an u

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de